Chimerix Crashes On Ph III Brincidofovir Flop; Dead End?

Shares of Chimerix Inc. crashed on Dec. 28 – plummeting as low as 82% – on word the firm's Phase III SUPPRESS trial of its oral antiviral brincidofovir failed to achieve its primary endpoint of preventing clinically significant cytomegalovirus (CMV) infection in patients through week 24 after undergoing hematopoietic cell transplantation (HCT).